VGNX -- Variagenics, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VGNX -- Variagenics, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (75)	10/20/2001 12:52:31 PM
From: Miljenko Zuanic	of 269

As you know small molecules also have skin rash as side effects, so my thought was that it has to do something with receptor(s) itself. "Little knowledge is dangerous things" is as well applicable to me. <<Pharmacokinetic modeling of preclinical data predicted biological activity of ABX-egf at doses around 1.0 mg/kg, which would yield average serum concentrations >5 mg/ml in patients.>> and <<Additional patients are currently being evaluated at the 1.5 mg/kg and 2.0 mg/kg dose levels, without a 2x loading dose, in order to determine the maximum tolerated dose. Study results will be reported at the conference.>> This somehow contradict "very potent". My thought was that 0.5 mg/kg should be sufficient. After BMY license C225 (overpaid?, why?) EGFr field and how it should be evaluated did change and become more complicated. I wish that I can explain and understand, but I can't. :( Yes, there is nothing spectacular in CI-1033. It is just example that hitting multiple targets with single molecule may be better way to suppress GFs? Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next